title: Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction.
abstract: BACKGROUND
  The circulating concentration of PlGF is reported to be lower in patients experiencing preeclampsia and patients delivering a small for gestational age (SGA) neonate. To evaluate the predictive value of circulating PlGF for preeclampsia and adverse outcome in patients with suspected preeclampsia or intrauterine growth restriction (IUGR).
  
  
  RESULTS
  A double blind prospective study. We enrolled 96 women for suspected preeclampsia or IUGR, and measured plasma levels of PlGF (Triage®) at enrolment. We defined adverse outcome as severe preeclampsia, SGA neonate (<10(th) centile) or elective delivery for maternal or fetal complication. Severe adverse outcome was studied among patients included <34 weeks gestation (WG) and defined as eclampsia, HELLP syndrome, very SGA (<3(rd) centile) or elective delivery <34 WG. The mean logtransformed PlGF level was lower for women who experienced preeclampsia (2.9 vs 3.7, p = 0.02), and was markedly lower for patients who experienced adverse outcome (2.9 vs 4.3, p<0.001). The odds of presenting an adverse outcome were higher for the lowest tertile of PlGF compared to the higher (OR = 13 , 95% CI [3-50]). For severe adverse outcome, odds were respectively for the lowest and intermediate tertile as compared with the higher tertile : OR = 216, 95% CI [18-2571]; and OR = 17, 95% CI [3-94]. When included <34 WG, patients with a PlGF level <12 pg/ml experienced a severe adverse outcome in 96% of cases (24/25), and only 1 of 20 patients with a PlGF level >5(th) centile experienced a severe adverse outcome within 15 days (5%).
  
  
  CONCLUSIONS
  Among women with suspected preeclampsia or IUGR, PlGF helps identify women who will experience an adverse outcome and those who will not within a time period of 15 days.
authors.affiliation: Cochin Hospital, APHP, Paris-Descartes University, Paris, France. jeannesibiude@yahoo.fr
authors.forename: Jeanne
authors.initials: J
authors.lastname: Sibiude
authors.forename: Jean
authors.initials: J
authors.lastname: Guibourdenche
authors.forename: Marie-Danielle
authors.initials: MD
authors.lastname: Dionne
authors.forename: Camille
authors.initials: C
authors.lastname: Le Ray
authors.forename: Olivia
authors.initials: O
authors.lastname: Anselem
authors.forename: Raphaël
authors.initials: R
authors.lastname: Serreau
authors.forename: François
authors.initials: F
authors.lastname: Goffinet
authors.forename: Vassilis
authors.initials: V
authors.lastname: Tsatsaris
mesh_terms: D000328:Adult; D015415:Biomarkers; D004311:Double-Blind Method; D005260:Female; D005317:Fetal Growth Retardation / Q000378:metabolism*; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D008137:Longitudinal Studies; D015233:Models, Statistical; D016017:Odds Ratio; D000072483:Placenta Growth Factor; D011225:Pre-Eclampsia / Q000097:blood / Q000378:metabolism*; D011237:Predictive Value of Tests; D011247:Pregnancy; D011257:Pregnancy Proteins / Q000378:metabolism*; D011446:Prospective Studies; D015203:Reproducibility of Results; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; C000608036:PGF protein, human; D011257:Pregnancy Proteins; D000072483:Placenta Growth Factor